These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38650446)

  • 1. Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case report.
    Li L; Yu D; Yang J; Zhang F; Zhang D; Lin Z; Zhai M; Wang J; Zhang T; Zhao L
    Cancer Biol Ther; 2024 Dec; 25(1):2338644. PubMed ID: 38650446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
    Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
    Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report.
    Zhang JW; Yang X; Pan B; Xu Y; Lu X; Zhao HT
    World J Surg Oncol; 2023 Mar; 21(1):108. PubMed ID: 36973682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma.
    Dreikhausen L; Kusnik A; Schulte N; Eckardt M; Teufel A; Gaiser T; Ebert M; Zhan T
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):409-410. PubMed ID: 34551034
    [No Abstract]   [Full Text] [Related]  

  • 5. PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
    Wang Z; Zeng T; Li Y; Zhang D; Yuan Z; Huang M; Yang Y; Zhou W
    Front Immunol; 2021; 12():799822. PubMed ID: 35003124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
    Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
    Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma].
    Zhou BJ; Wang WS; Yin Y; Yang J; Zhu XL; Ni CF
    Zhonghua Nei Ke Za Zhi; 2024 Aug; 63(8):769-775. PubMed ID: 39069865
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
    Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
    Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
    Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
    Front Immunol; 2021; 12():744571. PubMed ID: 34603331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
    Chen TH; Chang PM; Yang MH
    J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors.
    Al-Toubah T; Schell MJ; Morse B; Haider M; Valone T; Strosberg J
    ESMO Open; 2024 Apr; 9(4):102386. PubMed ID: 38507897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma.
    Zhang Z; Wang G; Du L; Zhao J; Pan L; Zhang G; Wang F; Liu R
    Front Immunol; 2023; 14():1124482. PubMed ID: 37292215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
    Liu Z; Li X; He X; Xu Y; Wang X
    BMC Cancer; 2019 Nov; 19(1):1062. PubMed ID: 31703571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 18. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
    Zhang W; Luo C; Zhang ZY; Zhang BX; Chen XP
    Front Immunol; 2022; 13():1079342. PubMed ID: 36700218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.